SLFN11 is associated with responses to DNA-damaging agents (65), and its expression in ACC surgical specimens in the present study supports the possibility that SLFN11 may serve as a marker to predict ACC patient responsiveness to specific treatments (Supplementary Fig. S4). The gene discussed is SLFN11; the disease is adrenal cortex carcinoma.